http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109528718-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 |
| filingDate | 2018-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109528718-B |
| titleOfInvention | A kind of medicine for treating cervical cancer and use thereof |
| abstract | The invention belongs to the field of medicine, and relates to a medicine for treating cervical cancer and use thereof. The medicine is prepared from aspirin, a 1-position substituted β-carboline and pharmaceutical preparation excipients. Wherein the 1-substituted β-carboline is selected from 1-acetyl-β-carboline or 1-methoxycarbonyl-β-carboline, preferably 1-acetyl-β-carboline. The mass ratio of aspirin to 1-acetyl-β-carboline in the medicine is 10:1 to 17:1. The dosage form of the drug is preferably an oral solid preparation. In the experimental study, it was found that the combination of 1-acetyl-β-carboline and aspirin has an inhibitory effect on the cervical cancer transplantation model, and has the potential to be applied to the treatment of cervical cancer. |
| priorityDate | 2018-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.